Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-11 | SenzaGen | NOTICE OF ANNUAL GENERAL MEETING OF SENZAGEN AB (Publ) | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
NOTICE OF ANNUAL GENERAL MEETING OF SENZAGEN AB (Publ)The shareholders of SenzaGen AB (Publ.), company registration number 556821–9207, (“the Company”) are hereby given notice of the annual general meeting (“AGM”) on 15 May 2024 at 3 PM in The Spark Sharience, Medicon Village, Scheeletorget 1, Lund, Sweden. The meeting will be held in Swedish. Eligibility to attend the AGM and notice of attendance Shareholders must also give notice of their attendance and that of any proxies (max two) by Thursday, 9 May 2024 by mail to SenzaGen AB, Medicon Village, 223 81 Lund, Sweden, or by email to anmalan@senzagen.com. The notice of attendance must include the full name, personal or company registration number, address, phone number and, if applicable, information about proxies or other representatives. If applicable, the notice of attendance should be followed by a proxy document, a certificate of registration and other documentation. Nominee shares Proxies Proposed agenda
Proposed resolutions Item 1: Election of AGM chairman Item 8.b Items 9–11: The Nomination Committee’s proposals are as follows: The Nomination Committee proposes that the board shall consist of five directors and no alternates. The number of auditors and the number of deputy auditors shall each be one. The Nomination Committee proposes that the directors’ fees shall be SEK 200,000 (SEK 200,000 previous year) for each director elected by the AGM who is not employed by the Company and SEK 400,000 (SEK 400,000) for the board chairman, for a total amount of SEK 1,200,000 (SEK 1,200,000). The Nomination Committee proposes that the auditor’s fees shall be payable on the basis of approved invoices. The Nomination Committee proposes the re-election of Carl Borrebaeck, Ian Kimber, Ann-Christin Malmborg Hager, Paula Zeilon and Paul Yianni as directors. It is also proposed that Carl Borrebaeck be re-elected as chairman of the board. The Nomination Committee proposes the re-election of Authorized Public Accountant Mats-Åke Andersson as the Company’s auditor, with Authorized Public Accountant Martin Gustafsson as deputy auditor. Information about the members proposed for re-election can be found on the Company’s website www.senzagen.com. Item 12: Scope Fundamental principle and deliberation process for matters of remuneration The board as a whole comprises the remuneration committee with the task of deliberating on the remuneration policies for senior executives that will be presented to the AGM for resolution. The board resolves on matters regarding the salary and employment conditions of the CEO. Fixed salary Variable remuneration (a) The individual variable annual fee can range from 8% to 25% of the fixed remuneration depending on the position. The ultimate amount payable depends on the degree of attainment primarily of set financial goals as well as qualitative goals to a limited extent. (b) The long-term incentive program is intended to serve as a complement to the individual variable annual fee. The board may deliberate on whether to propose share-related or share price-related programs for senior executives to the AGM. Non-monetary remuneration Termination and severance pay Fee for services that do not constitute board work The total amount of remuneration that has been or will be paid directly or indirectly by the Company to senior executives is disclosed in its entirety in the Company’s 2023 annual report, which is available on the Company’s website, www.senzagen.com. Item 13: Resolution to authorize the board to issue shares, stock options and/or convertibles To prevent the Company’s current shareholders from being disadvantaged in relation to external investors who could subscribe for shares in the Company, the board plans, by virtue of this authorization, to set the issue price on market terms (meaning that an issue discount on market terms may be provided) for issues with the shareholders’ preemptive rights waived. If found appropriate by the board to enable delivery of shares in conjunction with a share issue as set out above, a subscription price equal to the nominal (quotient) value of the shares can be used. As a result, the maximum number of shares that may be issued is 6,047,081, and the Company’s share capital may be increased by a maximum of SEK 302,354.05. The board, or those designated by the board, are proposed to be granted authorization to make adjustments as may be necessary in conjunction with registering the resolution with the Swedish Companies Registration Office (Bolagsverket). Item 14: Resolution on directed share issue of a maximum of 750,000 stock options The following rules shall apply to the directed share issue: With the shareholders’ preemptive rights waived, employees of the Company and the Group shall be entitled to subscribe for the stock options as follows:
Oversubscription cannot take place. The stock options must be subscribed for by 1 June 2024 on a separate subscription list. The board shall be entitled to extend the subscription period but no later than until 1 November 2024. The subscriber is entitled to subscribe for stock options free of charge. The market value of the option shall be calculated using the Black-Scholes pricing model subject to barrier conditions to calculate the Company’s social security expenses. The valuation of the options shall be performed by an independent valuation institute or auditing firm. A preliminary calculation (7 March 2024) based on an exercise price and barrier conditions at the time of exercising the stock options of SEK 6.00 per share results in an option value of SEK 1.20. The stock options allotted will be offered for subscription free of charge. Such an offer to allot stock options must be provided within 10 banking days of the date a resolution to allot options has been passed. Each stock option entitles the holder to subscribe for one new share in the Company in exchange for cash payment, provided that the barrier conditions have been met, during the period from 1 June 2027 to 30 September 2027 or the earlier date set out in the option rules. However, the stock options shall be exercisable at an earlier point in time in the event of a merger, compulsory redemption, liquidation, or similar circumstances. Payment for shares subscribed for by exercising stock options shall be made in cash at an exercise price of 100% of the average of the listed volume-weighted price paid for each trading day as per Nasdaq First North Growth Market’s official price list for shares in the Company during the period from 29 April 2024 to 14 May 2024. The exercise price established in this manner shall be rounded to the nearest whole tenth in SEK öre, with SEK 5 öre rounded down. For each individual participant in the stock option plan, 80 percent of all allotted stock options are subject to barrier conditions, and these 80 percent of the stock options can only be exercised to subscribe for shares once the volume-weighted price paid measured per trading day as per the Nasdaq First North Growth Market’s official price list for shares is higher than the respective barrier level. The barrier levels are calculated as a percentage of the average volume-weighted price as per the Nasdaq First North Growth Market’s official price list for shares in the Company during the period from 29 April 2024 to 14 May 2024 (“ the Barrier Price ”). The barrier levels shall consist of two barriers, with the first barrier accounting for 25 percent (“ Barrier 1 ”) and the second barrier accounting for 55 percent (“ Barrier 2 ”) of all the stock options allotted to participants, in accordance with what is set out below.
Barrier 1 and Barrier 2 established in this manner shall be rounded to the nearest whole tenth in SEK öre, with SEK 5 öre rounded down. The barriers shall be recalculated in the same way as for the redemption price in the option rules. New shares subscribed for by exercising Stock options entitle the holder to dividends for the first time on the dividend record date most immediately following the date the new share issue was registered with the Swedish Companies Registration Office and Euroclear Sweden AB. The purpose of the share issue and the reason for waiving shareholders’ preemptive rights is to implement an option program suited for allotment to key personnel in the Company so that they can be offered the opportunity to participate in the growth in value of the Company’s stock. This is expected to lead to stronger interest in the Company’s growth – as well as the Company’s share price performance – and stimulate continued company loyalty over the coming years. In conjunction with the transfer of the stock options to the participants in the program, the Company reserves the right to buy back all stock options if the participant’s employment is terminated or if the participant wishes to transfer the stock options to another party during the period until 31 May 2027. The complete rules for the stock options will be kept available on the Company’s premises and on the Company’s website no later than two (2) weeks prior to the AGM. These rules include that the exercise price and the number of shares to which a stock options entitles the holder to subscribe for may be recalculated in certain cases. It is proposed that the board or those designated by the board be authorized to make minor adjustments to this resolution as may be necessary in conjunction with registration with the Swedish Companies Registration Office and, if applicable, with Euroclear Sweden AB. Deliberation on the board’s proposed 2024/2027 incentive program, the costs of the program, other outstanding stock-based incentive programs, dilution Valuation Expenses and impact on financial ratios The total cost of social security contributions depends on the number of options that will be added and on the value of the benefit that the participant will eventually receive at the time of the allocation, but also in which countries the participants reside and what percentages apply to social security contributions in these countries. In cases where the participant resides in a country other than Sweden and is employed by another wholly-owned company in the Group (the “Employer Company”), both salary benefits and social security contributions may arise in the Employer Company when the option is exercised for the purchase of shares. In the event of positive performance of the share price in conjunction with the exercise of the option, the option program will result in costs in the form of social security contributions for the Employer Company. Costs for social security contributions are estimated to amount to approximately SEK 0.6 million, assuming the allotment and exercise of 135,000 options, average social security contributions of 35 percent and an assumed share price of SEK 18.00 when the options are exercised. The program is expected to have a marginal impact on the Company’s financial ratios. Dilution There are currently several stock-based incentive programs outstanding in the Company, as below: The 2021/2024 L series incentive program is for a maximum of 587,500 stock options, and 372,000 of which have been subscribed entitling the holder to subscribe for new shares at a price of SEK 14.30 from 1 June 2024 to 30 September 2024. The 2022/2025 incentive program is for a maximum of 812,500 stock options, and 637,500 of which have been subscribed entitling the holder to subscribe for new shares at a price of SEK 9.60 from 1 June 2025 to 30 September 2025. The 2023/2026 incentive program is for a maximum of 1,015,000 stock options, and 720,000 of which have been subscribed entitling the holder to subscribe for new shares at a price of SEK 11.20 from 1 June 2026 to 30 September 2026. If all previously issued stock options and stock options issued in the 2024/2027 incentive program are exercised, the dilution may amount to a maximum of approximately 9.3 percent of the total number of shares and votes in the Company (calculated on the basis of the number of existing shares in the Company and taking into account other outstanding stock options). Other outstanding stock-based incentive programs Majority requirement Shareholders representing at least nine tenths of both the votes cast and the shares represented at the AGM must vote for the resolution under item 14 for it to be deemed duly passed. GENERAL INFORMATION Number of shares and votes Documents Shareholders are reminded of their right, at the AGM, to request disclosures from the board and CEO under Chapter 7 Section 32 of the Swedish Companies Act. Personal data processing * * * * * Lund, March 2024, |
||||
2024-04-11 | SenzaGen | Kallelse till årsstämma i SenzaGen AB (Publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-25 | SenzaGen | SenzaGen’s chemical industry orders continue to increase | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-25 | SenzaGen | SenzaGens orderingång från kemikalieindustrin fortsätter att öka | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-22 | SenzaGen | SenzaGen publicerar årsredovisningen för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-03-22 | SenzaGen | SenzaGen’s Annual Report 2023 published | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-03-06 | SenzaGen | SenzaGen presenterar och anordnar paneldebatt på SOT Annual Meeting & ToxExpo 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-06 | SenzaGen | SenzaGen presents and hosts a panel discussion at the SOT Annual Meeting & ToxExpo 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-20 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med SenzaGen - Carnegie Investment Bank - 20 feb 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-15 | Penser Access by Carnegie | Penser Access by Carnegie: SenzaGen - Bra position in i 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-15 | Redeye | Redeye: SenzaGen H2 - Continued growth and aligned with our expectations | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-14 | SenzaGen | SenzaGen’s 2023 Year-End Report: Company approaching breakeven with SEK 50 million in sales | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-14 | SenzaGen | SenzaGens bokslutskommuniké 2023: Bolaget närmar sig break-even med en omsättning på 50 miljoner kronor | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-07 | SenzaGen | Invitation to the presentation of SenzaGen’s year-end report 2023 on Feb 14 at 10.00 CET | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-07 | SenzaGen | Inbjudan till presentation av SenzaGens bokslutskommuniké 2023 den 14 februari kl 10.00 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-10 | SenzaGen | SenzaGen får uppföljningsorder värd 1,5 MSEK för GARD®skin-tester till kemikalieindustrin | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-10 | SenzaGen | SenzaGen receives a follow-up order worth 1.5 million SEK for GARD®skin for the chemical industry | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-18 | SenzaGen | SenzaGen får order på 1,7 MSEK från ny världsledande kund inom biotech-industrin | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-18 | SenzaGen | SenzaGen secures SEK 1.7m order from a new global biotech industry leader | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-29 | SenzaGen | SenzaGen byter likviditetsgarant till Carnegie | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-29 | SenzaGen | SenzaGen changes its market maker to Carnegie | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | SenzaGen | SenzaGen är ett av Sveriges snabbast växande teknikbolag | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | SenzaGen | SenzaGen ranked one of Sweden's fastest-growing technology companies | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | SenzaGen | SenzaGen secures strategically important order from new customer, a world leader in fast-moving consumer goods (FMCG) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | SenzaGen | SenzaGen säkrar strategiskt viktig order från ny världsledande kund inom FMCG (dagligvaror) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-25 | SenzaGen | Continued growth and expanded customer base for SenzaGen during the third quarter | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-25 | SenzaGen | Fortsatt tillväxt och breddad kundbas för SenzaGen under tredje kvartalet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-18 | SenzaGen | SenzaGen presenterar på BioStock Life Science Summit den 26 oktober | Pressreleaser | Visa Stäng |
|
||||
2023-09-28 | SenzaGen | SenzaGen continues to collaborate with RIFM in non-animal photosensitization and fragrance safety – receives a new grant worth SEK 1.6m | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-28 | SenzaGen | SenzaGen fortsätter att samarbeta med RIFM inom djurfri fotosensibilisering och doftsäkerhet – får nytt uppdrag värt 1,6 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-25 | Penser Access | Penser Access: På väg mot kassaflödesneutralitet - SenzaGen | Pressreleaser | Visa Stäng |
|
||||
2023-08-25 | Redeye | Redeye: SenzaGen H1 2023 - Increased customer base | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-24 | SenzaGen | SenzaGens halvårsrapport 2023: Fortsatt tillväxt, förbättrad bruttomarginal och minskad förlust | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-24 | SenzaGen | SenzaGen’s 2023 Half-Year Report: Continued growth, improved gross margin and lower loss | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-07-07 | SenzaGen | SenzaGen stärker marknadsnärvaron genom utökade distributionskanaler | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-07 | SenzaGen | SenzaGen strengthens its market presence with expanded distribution channels | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-12 | Penser Access | Penser Access: Intervju med SenzaGen - Erik Penser Bank - 11 maj 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-11 | SenzaGen | SenzaGen utser likviditetsgarant | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-11 | SenzaGen | SenzaGen appoints market maker | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | SenzaGen | Kommuniké från årsstämma i SenzaGen AB den 4 maj 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | SenzaGen | Report from AGM of SenzaGen AB on 4 May 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Penser Access | Penser Access: Giftfri tillväxt - SenzaGen | Pressreleaser | Visa Stäng |
|
||||
2023-04-26 | SenzaGen | Uthållig och stark försäljningsutveckling för SenzaGen under årets första kvartal | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-26 | SenzaGen | Consistent and strong sales growth for SenzaGen in Q1 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|